Compare National Beverage Corp. (FIZZ) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Cassava Sciences Inc — how do they compare? National Beverage Corp. trades at $30.61 (market cap $2.89B), while Cassava Sciences Inc trades at $0.82 (market cap $39.40M). The key difference: National Beverage Corp. is far larger — about 73.4× Cassava Sciences Inc's market cap, and National Beverage Corp. is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Cassava Sciences Inc for 37 Days on average.
| FIZZ | FLNA | |
|---|---|---|
Market Cap | $2.89B | $39.40M |
Volume | 553,950 | 759,018 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $4.64 |
52-Week Low | $29.20 | $0.68 |
Typical Hold Time | 33 Days | 37 Days |
Enterprise Value | $2.84B | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
National Beverage Corp. (FIZZ) trades at $30.36, up 2.57% today, showing mixed signals with a bullish technical outlook but bearish analyst sentiment. The stock faces margin pressure with recent earnings misses and declining revenue growth, though profitability metrics remain strong with 14.81% net margin and 40.13% ROE. Recent news highlights institutional buying and a $3.25 special dividend payment.
FIZZ presents a cautious investment case with strong profitability offset by growth challenges. The company's high ROE and solid margins provide fundamental support, but consecutive earnings misses and tariff-related margin compression create near-term headwinds. Analyst consensus leans bearish with 50% sell ratings, suggesting limited upside potential despite technical strength.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
